In this video, Prof. Hanny Al-Samkari of Harvard Medical School shares key insights from the VEHIT-2 Phase III randomized trial evaluating ianalumab in early second-line immune thrombocytopenia (ITP). He discusses…

Lymphoma diagnosis and treatment are entering a phase of accelerated evolution, with breakthrough therapies and innovative research continuously reshaping clinical practice. From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was grandly held in Orlando. At this year’s congress, multidimensional and in-depth innovations emerged across both aggressive lymphoma precision therapy and long-term disease management for indolent lymphomas.

For many years, the treatment of pediatric lymphoma has been challenged by marked variability in therapeutic response and poor outcomes in relapsed or refractory cases. Under the leadership of Professor Zhang Yonghong, his team has driven the development of standardized and precision-based treatment strategies through long-term research and clinical innovation. In particular, they have achieved major breakthroughs in the management of relapsed and refractory pediatric lymphoma. By integrating molecular biology–based risk stratification and pioneering the application of CAR-T therapy, the team has significantly improved treatment outcomes, elevating the overall standard of pediatric lymphoma care in China. In this issue, Hematology Frontier invited Professor Zhang Yonghong to share insights into his team’s exploration and innovation in precision diagnosis and treatment of pediatric lymphoma, as well as his perspectives on future directions.

At ASH 2025, Prof. Jeff Sharman from the Willamette Valley Cancer Research Institute shares key clinical insights on mosunetuzumab, focusing on its safety, efficacy, and durability of response, particularly in…

At ASH 2025, Dr. Shannuo Li from the University of Utah, USA shares her perspective on emerging strategies for multi-target immune engagement, exploring the potential of simultaneously targeting BCMA, CD38,…

At the recent Annual Meeting of the American Society of Hematology (ASH), the team led by Professor Cai Zhen and Professor He Jingsong from The First Affiliated Hospital, Zhejiang University School of Medicine, had 12 studies accepted, comprehensively showcasing systematic investigations in multiple myeloma ranging from basic research to clinical translation. These studies focused on key scientific questions including the roots of disease relapse, mechanisms of drug resistance, prognostic evaluation, and therapeutic strategies, forming an integrated evidence chain from mechanistic discovery to clinical application. During the meeting, Hematology Frontier invited Professor Cai Zhen to provide an in-depth interpretation of the team’s research achievements and outline future research plans, offering valuable academic insights to advance the diagnosis and treatment of multiple myeloma.

Multiple myeloma is one of the most common hematologic malignancies, characterized by marked biological heterogeneity and a complex disease course. Achieving deep and durable remission at initial diagnosis is critical for improving long-term outcomes. At the recent Annual Meeting of the American Society of Hematology (ASH), Professor Du Juan’s study was selected for oral presentation, evaluating the use of dual-target BCMA/CD19 FasTCAR-T therapy as first-line treatment in patients with newly diagnosed multiple myeloma (NDMM). The encouraging results provide strong evidence supporting the earlier use of CAR-T therapy. Hematology Frontier invited Professor Du Juan for an in-depth discussion of the study and future research directions.

The 67th Annual Meeting of the American Society of Hematology (ASH) was held from December 6 to 9, 2025, in Orlando, bringing together the latest global advances in hematology research and clinical practice. At this year’s meeting, the team led by Professor Hu Kai from Beijing Gaobo Hospital presented seven studies focusing on CAR-T cell therapy across different types of relapsed/refractory lymphoma, including B-cell lymphoma, central nervous system lymphoma, T-cell lymphoma, as well as combined strategies involving CAR-T therapy and hematopoietic stem cell transplantation. These studies provide important evidence supporting the further development of individualized treatment strategies. Oncology Frontier – Hematology Frontier invited Professor Hu Kai to provide an in-depth interpretation of these key findings and their clinical significance.